Fig. 2: Progression-free survival in all resected patients and stratified by treatment arm, stage and major pathological response. | Nature Communications

Fig. 2: Progression-free survival in all resected patients and stratified by treatment arm, stage and major pathological response.

From: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I–III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial

Fig. 2

Progression-free survival for all surgically resected patients (n = 52) (a) and in each arm of the trial (b). PFS in patients with clinical stages I/II (c) and clinical stage III (d) in each arm. PFS in all 52 patients with and without MPR (e). PFS in 34 patients without MPR in each arm of the trial (f). All panels, Kaplan-Meier survival method. Panels (b) through (f), log rank test p-values. Source data for all panels are provided as a Source Data file.

Back to article page